BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewis EF. Assessing the impact of heart failure therapeutics on quality of life and functional capacity. Curr Treat Options Cardiovasc Med 2013;15:425-36. [PMID: 23625508 DOI: 10.1007/s11936-013-0249-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Lewis EF, Kim HY, Claggett B, Spertus J, Heitner JF, Assmann SF, Kenwood CT, Solomon SD, Desai AS, Fang JC, McKinlay SA, Pitt BA, Pfeffer MA; TOPCAT Investigators. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. Circ Heart Fail 2016;9:e001937. [PMID: 26962133 DOI: 10.1161/CIRCHEARTFAILURE.114.001937] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
2 Schulz M, Griese-Mammen N, Schumacher PM, Anker SD, Koehler F, Ruckes C, Rettig-Ewen V, Wachter R, Trenk D, Böhm M, Laufs U. The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial. ESC Heart Fail 2020. [PMID: 32700409 DOI: 10.1002/ehf2.12904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gorodeski EZ, Goyal P, Hummel SL, Krishnaswami A, Goodlin SJ, Hart LL, Forman DE, Wenger NK, Kirkpatrick JN, Alexander KP; Geriatric Cardiology Section Leadership Council, American College of Cardiology. Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future. J Am Coll Cardiol 2018;71:1921-36. [PMID: 29699619 DOI: 10.1016/j.jacc.2018.02.059] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 19.7] [Reference Citation Analysis]
4 Lawson CA, Solis-Trapala I, Dahlstrom U, Mamas M, Jaarsma T, Kadam UT, Stromberg A. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018;15:e1002540. [PMID: 29584734 DOI: 10.1371/journal.pmed.1002540] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
5 Chavanon ML, Inkrot S, Zelenak C, Tahirovic E, Stanojevic D, Apostolovic S, Sljivic A, Ristic AD, Matic D, Loncar G, Veskovic J, Zdravkovic M, Lainscak M, Pieske B, Herrmann-Lingen C, Düngen HD. Regional differences in health-related quality of life in elderly heart failure patients: results from the CIBIS-ELD trial. Clin Res Cardiol 2017;106:645-55. [PMID: 28361371 DOI: 10.1007/s00392-017-1101-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Joyce E, Chung C, Badloe S, Odutayo K, Desai A, Givertz MM, Nohria A, Lakdawala NK, Stewart GC, Young M, Weintraub J, Stevenson LW, Lewis EF. Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction. JACC Heart Fail 2016;4:184-93. [PMID: 26874379 DOI: 10.1016/j.jchf.2015.12.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
7 Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, Giannetti N, Januzzi JL, Piña IL, Lam CSP, Ponikowski P, Sattar N, Verma S, Brueckmann M, Jamal W, Vedin O, Peil B, Zeller C, Zannad F, Packer M; EMPEROR-Reduced Trial Committees and Investigators. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021;42:1203-12. [PMID: 33420498 DOI: 10.1093/eurheartj/ehaa1007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
8 Butler J, Stebbins A, Melenovský V, Sweitzer NK, Cowie MR, Stehlik J, Khan MS, Blaustein RO, Ezekowitz JA, Hernandez AF, Lam CSP, Nkulikiyinka R, O'Connor CM, Pieske BM, Ponikowski P, Spertus JA, Voors AA, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. Circ Heart Fail 2022;15:e009337. [PMID: 35656822 DOI: 10.1161/CIRCHEARTFAILURE.121.009337] [Reference Citation Analysis]
9 Maslov MY, Foianini S, Orlov MV, Januzzi JL, Lovich MA. A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. J Card Fail 2018;24:773-82. [PMID: 30347271 DOI: 10.1016/j.cardfail.2018.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
10 Lewis EF, Claggett BL, Mcmurray JJV, Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai AS, Solomon SD, Swedberg K. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail 2017;10. [DOI: 10.1161/circheartfailure.116.003430] [Cited by in Crossref: 83] [Cited by in F6Publishing: 29] [Article Influence: 16.6] [Reference Citation Analysis]